Neuroprotection in subarachnoid hemorrhage.
Despite advances in aneurysm ablation and the initial management of patients presenting with aneurysmal subarachnoid hemorrhage, delayed cerebral ischemia remains a significant source of morbidity. Traditionally, delayed cerebral ischemia was thought to be a result of vasospasm of the proximal intracranial vessels, and clinical trials have relied largely on radiographic evidence of vasospasm as a surrogate for functional outcome. However, a number of trials have demonstrated a dissociation between angiographic vasospasm and outcome, and more recent data suggest that other mechanisms of injury, such as microvascular dysfunction and complex neuronal-glial interactions, may influence the development of delayed ischemic deficit after aneurysmal subarachnoid hemorrhage. Our evolving understanding of the pathophysiology of delayed cerebral ischemia may offer the opportunity to test new therapeutic strategies in this area and improve clinical trial design.
Duke Scholars
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Vasospasm, Intracranial
- Subarachnoid Hemorrhage
- Neuroprotective Agents
- Neurology & Neurosurgery
- Humans
- Brain
- 4201 Allied health and rehabilitation science
- 3209 Neurosciences
- 3202 Clinical sciences
- 1109 Neurosciences
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Vasospasm, Intracranial
- Subarachnoid Hemorrhage
- Neuroprotective Agents
- Neurology & Neurosurgery
- Humans
- Brain
- 4201 Allied health and rehabilitation science
- 3209 Neurosciences
- 3202 Clinical sciences
- 1109 Neurosciences